Omicron Sub-Lineages (BA.1.1.529 + BA.*) Current Status in Ecuador

Viruses

卷:14

USFQ-COVID-19 Consortium¹  CRN Influenza y OVR—INSPI¹  Gabriel Morey-León²  Juan Carlos Fernández-Cadena³  Diana Gutiérrez-Pallo⁴  Damaris Alarcón-Vallejo⁴  Andrés Herrera-Yela⁴  Andrés Carrazco-Montalvo⁴  Isaac Armendáriz-Castillo⁵  Leandro Patiño⁶  Karen Muñoz-Mawyin⁷  Derly Andrade-Molina⁷ 

[1] ;

[2] Facultad de Ciencias Medicas, Universidad de Guayaquil, Guayaquil 090514, Ecuador;

[3] INTERLAB, Guayaquil 090512, Ecuador;

[4] Instituto Nacional de Investigación en Salud Pública “Leopoldo Izquieta Pérez”, Centro de Referencia Nacional de Genómica, Secuenciación y Bioinformática, Quito 170136, Ecuador;

[5] Instituto Nacional de Investigación en Salud Pública “Leopoldo Izquieta Pérez”, Coordinación Zonal 9, Quito 170136, Ecuador;

[6] Instituto Nacional de Investigación en Salud Pública “Leopoldo Izquieta Pérez”—Dirección Técnica de Investigación, Desarrollo e Innovación, Guayaquil 170403, Ecuador;

[7] Omics Sciences Laboratory, Faculty of Medical Sciences, Universidad Espíritu Santo, Samborondón 092301, Ecuador;

关键词: COVID-19;    Omicron;    sub-lineages;    Ecuador;   

DOI  :  10.3390/v14061177

来源: DOAJ

【 摘 要 】

The Omicron variant of SARS-CoV-2 is the latest pandemic lineage causing COVID-19. Despite having a vaccination rate ≥85%, Ecuador recorded a high incidence of Omicron from December 2021 to March 2022. Since Omicron emerged, it has evolved into multiple sub-lineages with distinct prevalence in different regions. In this work, we use all Omicron sequences from Ecuador available at GISAID until March 2022 and the software Nextclade and Pangolin to identify which lineages circulate in this country. We detected 12 different sub-lineages (BA.1, BA.1.1, BA.1.1.1, BA.1.1.14, BA.1.1.2, BA.1.14, BA.1.15, BA.1.16, BA.1.17, BA.1.6, BA.2, BA.2.3), which have been reported in Africa, America, Europe, and Asia, suggesting multiple introduction events. Sub-lineages BA.1 and BA.1.1 were the most prevalent. Genomic surveillance must continue to evaluate the dynamics of current sub-lineages, the early introduction of new ones and vaccine efficacy against evolving SARS-CoV-2.

【 授权许可】

Unknown